These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 3851698)
21. Role of IFN-alpha/beta and IL-12 in the activation of natural killer cells and interferon-gamma production during experimental infection with Trypanosoma cruzi. Une C; Andersson J; Orn A Clin Exp Immunol; 2003 Nov; 134(2):195-201. PubMed ID: 14616777 [TBL] [Abstract][Full Text] [Related]
22. Restoration by recombinant interferon alpha A/D of host defense systems against tumor in immunosuppressed mice. Nishimura J; Mitsui K; Tanaka Y; Yamamoto R; Suhara Y; Ishitsuka H Clin Exp Metastasis; 1986; 4(1):35-44. PubMed ID: 3698367 [TBL] [Abstract][Full Text] [Related]
23. High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma. Pica F; Fraschetti M; Matteucci C; Tuthill C; Rasi G Anticancer Res; 1998; 18(5A):3571-8. PubMed ID: 9858941 [TBL] [Abstract][Full Text] [Related]
24. In vivo activation of murine natural killer cell functions by human recombinant DNA interleukin 2. Sayers T; Rossiter H; Chung J; Hren A; Armerding D Immunobiology; 1985 Apr; 169(3):303-18. PubMed ID: 3922876 [TBL] [Abstract][Full Text] [Related]
25. Genetic differences in the age-associated decrease in inducibility of natural killer cells by interferon-alpha/beta. Plett A; Murasko DM Mech Ageing Dev; 2000 Jan; 112(3):197-215. PubMed ID: 10687925 [TBL] [Abstract][Full Text] [Related]
26. Low doses of interferon alpha result in more effective clinical natural killer cell activation. Edwards BS; Merritt JA; Fuhlbrigge RC; Borden EC J Clin Invest; 1985 Jun; 75(6):1908-13. PubMed ID: 4008643 [TBL] [Abstract][Full Text] [Related]
27. Interferon-beta and recombinant IL 2 can both enhance, but by different pathways, the nonspecific cytolytic potential of T3- natural killer cell-derived clones rather than that of T3+ clones. van de Griend RJ; Ronteltap CP; Gravekamp C; Monnikendam D; Bolhuis RL J Immunol; 1986 Mar; 136(5):1700-7. PubMed ID: 3005399 [TBL] [Abstract][Full Text] [Related]
28. Role of natural killer cells in the destruction of circulating tumor emboli. Hanna N; Fidler IJ J Natl Cancer Inst; 1980 Oct; 65(4):801-9. PubMed ID: 6932529 [TBL] [Abstract][Full Text] [Related]
29. The NK-1.1(-) mouse: a model to study differentiation of murine NK cells. Koo GC; Dumont FJ; Tutt M; Hackett J; Kumar V J Immunol; 1986 Dec; 137(12):3742-7. PubMed ID: 3782794 [TBL] [Abstract][Full Text] [Related]
30. Natural killer activity in cloned cytotoxic T lymphocytes: regulation by interleukin 2, interferon, and specific antigen. Brooks CG; Holscher M; Urdal D J Immunol; 1985 Aug; 135(2):1145-52. PubMed ID: 2409140 [TBL] [Abstract][Full Text] [Related]
31. Modulatory role of thymosin-alpha-1 in normal bone-marrow haematopoiesis and its effect on myelosuppression in T-cell lymphoma bearing mice. Paul S; Sodhi A Immunol Lett; 2002 Jul; 82(3):171-82. PubMed ID: 12036599 [TBL] [Abstract][Full Text] [Related]
32. Thymosin beta 4 enhances NK cell cytotoxicity mediated by ICAM-1. Lee HR; Yoon SY; Kang HB; Park S; Kim KE; Cho YH; Kim S; Kim CW; Cho BJ; Lee WJ; Bang SI; Park H; Cho D Immunol Lett; 2009 Mar; 123(1):72-6. PubMed ID: 19369144 [TBL] [Abstract][Full Text] [Related]
33. Interaction between luteotrophic hormone (LH) and thymosin on natural killer cell activity in BALB/c mice. Rouabhia M; Ghanmi Z; Deschaux PA Immunology; 1988 Sep; 65(1):125-8. PubMed ID: 3181992 [TBL] [Abstract][Full Text] [Related]
34. Stimulation of genetic resistance to marrow grafts in mice by interferon-alpha/beta. Afifi MS; Kumar V; Bennett M J Immunol; 1985 Jun; 134(6):3739-45. PubMed ID: 2985694 [TBL] [Abstract][Full Text] [Related]
35. Type I interferon protects antiviral CD8+ T cells from NK cell cytotoxicity. Xu HC; Grusdat M; Pandyra AA; Polz R; Huang J; Sharma P; Deenen R; Köhrer K; Rahbar R; Diefenbach A; Gibbert K; Löhning M; Höcker L; Waibler Z; Häussinger D; Mak TW; Ohashi PS; Lang KS; Lang PA Immunity; 2014 Jun; 40(6):949-60. PubMed ID: 24909887 [TBL] [Abstract][Full Text] [Related]
36. Combined effect of fluconazole and thymosin alpha 1 on systemic candidiasis in mice immunosuppressed by morphine treatments. di Francesco P; Gaziano R; Casalinuovo IA; Belogi L; Palamara AT; Favalli C; Garaci E Clin Exp Immunol; 1994 Sep; 97(3):347-52. PubMed ID: 8082290 [TBL] [Abstract][Full Text] [Related]
37. In vitro modulation of human natural killer cell activity by interferon: generation of adherent suppressor cells. Uchida A; Yanagawa E; Kokoschka EM; Micksche M; Koren HS Br J Cancer; 1984 Oct; 50(4):483-92. PubMed ID: 6237664 [TBL] [Abstract][Full Text] [Related]
38. A species of human alpha interferon that lacks the ability to boost human natural killer activity. Ortaldo JR; Herberman RB; Harvey C; Osheroff P; Pan YC; Kelder B; Pestka S Proc Natl Acad Sci U S A; 1984 Aug; 81(15):4926-9. PubMed ID: 6589637 [TBL] [Abstract][Full Text] [Related]
39. Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats. Rasi G; Silecchia G; Sinibaldi-Vallebona P; Spaziani E; Pierimarchi P; Sivilia M; Tremiterra S; Garaci E Int J Cancer; 1994 Jun; 57(5):701-5. PubMed ID: 8194879 [TBL] [Abstract][Full Text] [Related]
40. Regulation of human natural killer cell cytotoxicity by recombinant leukocyte interferon clone A. Lotzová E; Savary CA; Gutterman JU; Quesada JR; Hersh EM J Biol Response Mod; 1983; 2(5):482-96. PubMed ID: 6644351 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]